Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home Clinical Page 11

News & Views

Latest News

Category: Clinical

See all

First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product in Turkey

Clinical, News,

Telix and Eczacıbaşı-Monrol Nuclear Products Co. are pleased to announce that the first patients have been dosed in Telix’s Phase III ZIRCON clinical...

Read more

First Patients Dosed in Clinical Trial of Novel Lung and Ovarian Cancer Theranostic

Clinical, News,

Telix announces first two patients dosed in phase I trial of lung & ovarian cancer...

Read more

First Patient Dosed in Renal Cancer Imaging Study in Japan

Clinical, News,

Telix announces the first patient has been dosed in a Phase I/II study of Telix’s renal cancer diagnostic imaging product TLX250-CDx in...

Read more

Telix Receives FDA Feedback on Phase 3 Trial Design for Prostate Cancer Therapy Product

Clinical, News,

Telix Pharmaceuticals Limited announces that the FDA has provided feedback that will enable the Company to finalize the Phase 3 PROSTACT...

Read more

Recommencement of ZIRCON Phase III Trial Recruitment in EU

Clinical, News,

Telix Pharmaceuticals Limited announces that the Company’s ZIRCON phase III trial of TLX250-CDx has recommenced patient recruitment in...

Read more

Telix Granted FDA Approval for ZIRCON Renal Cancer Imaging

Clinical, News,

Telix Pharmaceuticals Limited is pleased to announce that the FDA has approved the ZIRCON study for American...

Read more

NDA Clinical Briefing Package Submitted to the US FDA

Clinical, News,

Telix Pharmaceuticals announces that it has submitted a complete clinical briefing package to the US FDA for its first product...

Read more

ZIRCON Phase 3 IND Submitted to the US FDA

Clinical, News,

Telix Pharmaceuticals Limited announces that it has submitted a Phase 3 IND application to the FDA for...

Read more

TLX101 for Brain Cancer IPAX-1 Study Update

Clinical, News,

Telix Pharmaceuticals has released an update on the progress of its TLX101 product in the treatment of glioblastoma...

Read more

Telix Pharmaceuticals Program Update Q3 2019

Clinical, News,

Telix Pharmaceuticals Limited is pleased to release a Clinical Trial Program Update for Q3,...

Read more

Posts pagination

1 … 10 11 12

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings